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88 Poster Session-Ithe ND and non-ND groups with regards to age, sex, diagnosis and
conditioning regimen, or the number of days to resolution of neutro-
penia. There were no significant differences in the number of posi-
tive cultures between the groups during the neutropenic period.
However, after the resolution of neutropenia, there was a signifi-
cantly higher number of non-enteric gram-positive coccal infections
in the ND group compared to non-ND. There was also a trend to-
wards a higher incidence of C difficile, and a significantly higher in-
cidence of new positive surveillance cultures of VRE on rectal swabs
in the ND group.
Our findings show that there is no apparent benefit associated with
ND. However, more surprising is the finding that some infections
were more common with ND. It could be speculated that the micro-
bial content of the non-ND is higher and, in the setting of broad-
spectrum antimicrobial prophylaxis and therapy, such a diet could
contribute to reduced colonization with virulent microorganisms.
These findings suggest that additional studies are needed to investi-
gate the role of dietary restrictions. If our findings are confirmed,
a major change in an established but non-evidence-based practice
will be needed. An added benefit of the more liberal diet would be
greater palatability - which may contribute to reduction in the use
of TPN and better nutrition.241
SEVERE HEPATOCELLULAR INJURY AFTER HEMATOPOIETIC CELL
TRANSPLANTATION: INCIDENCE, ETIOLOGY, AND OUTCOME
Sakai, M.1, Strasser, S.I.2, McDonald, G.B.1 1Fred Hutchinson Cancer
Research Center, Seattle, WA; 2Royal Prince Alfred Hospital, Sydney,
NSW, Australia
Hepatic complications of transplant are a common cause of mor-
tality. While mild elevations of serum aminotransferase enzymes
(AST, ALT) do not carry an adverse prognosis, this is not the case
with severe hepatocellular injury.
Methods: We reviewed 6,225 consecutive patients transplanted
from 1992–2007 to determine the incidence, causes, and outcomes
of severe hepatocellular injury (defined as serum AST .1,500 U/L
during the time from day 0 to day 100).
Results: Severe hepatocellular injury occurred in 88 patients
(1.4%). Causes were Sinusoidal Obstruction Syndrome (SOS) (n 5
46), hypoxic hepatitis (n 5 33), Varicella Zoster Virus (VZV) hepa-
titis (n 5 4), drug-induced liver injury (N 5 2), and Unknown (n 5
3). The incidence declined from 1.9% in the 1990s to 1.1% recently
(due to a 5-fold decline in SOS as a cause and disappearance of VZV
hepatitis). VZV hepatitis was seen in 4 patients, all before 1999 and
none since. Severe drug injury was attributed to liposomal amphoter-
icin and to carboplatin/etoposide/melphalan, respectively. In
hypoxic hepatitis, peak serum AST was 3,545 U/L (range 1,380–25,
246) within days of shock or prolonged hypoxemia; the case fatality
rate was 88%. In SOS, AST increases occurred 2–6 weeks after diag-
nosis; peak AST was 2,252 U/L (range 1,437–8,281) and the case
fatality rate was 76%, with only total serum bilirubin able to distin-
guish survivors from those who died (2.7 mg/dL vs. 11.3 mg/dL,
respectively, p 5 0.0009).
Conclusions: Hepatic circulatory insults (sinusoidal injury from
the conditioning regimen, hypotension, hypoxemia) and not infec-
tion are the most common cause of severe hepatocellular injury. Al-
though the frequency of severe hepatocellular injury has declined
sharply because of a falling incidence of SOS and VZV hepatitis,
the case fatality rate remains high.242
GENERATION OF HLA-RESTRICTED T-LYMPHOCYTE RESPONSES
AGAINST RECOMBINANT INFLUENZAVIRUS HEMAGGLUTININ A/NEW
CALEDONIA BY AN IN VITRO UMBILICAL CORD BLOOD MODEL OF
DENDRITIC CELL VACCINATION
Decker, W.K.1, Li, S.1, Xing, D.1, Robinson, S.N.1, Yang, H.1,
Steiner, D.1, Shpall, E.J.1, Bollard, C.M.2, Safdar, A.3 1University of
Texas MD Anderson Cancer Center, Houston, TX; 2Baylor College of
Medicine, Houston, TX; 3University of Texas MD Anderson Cancer Cen-
ter, Houston, TX
Introduction: Influenza infection following treatment with
chemotherapy and/or concomitant radiation therapy remains asignificant cause of morbidity among immuncompromised patients
in the hospital setting. Further, such patients tend to seroconvert in-
efficiently and with suboptimal titers following prophylactic vaccina-
tion with either the standard or recombinant influenza vaccines.
Toward the goal of addressing this issue, we have developed an in vi-
tromodel of dendritic cell (DC) immunotherapy utilizing DCs gen-
erated from umbilical cord blood (UCB).
Methods: UCB monocytes were harvested by adherence, and
UCB DCs were generated by incubation in GM-CSF and IL-4. Im-
matureDCs were loaded with purified rHA protein [A/NewCaledo-
nia (H1N1)], matured with an inflammatory cytokine cocktail, and
used to stimulate autologous T-lymphocytes. T-lymphocyte prim-
ing and development were supported by supplementation with
IL-12, IL-2, IL-7, and IL-15. DC and T-cells were analyzed by
flow cytometry. Antigen specific responses were documented by
IFN-g ELISpot, 51Cr lysis, and tetramer staining. Recombinant
hemagglutinin HLA-restricted peptides were synthesized by
Sigma-Genosys (The Woodlands, Texas). MHC class II DR15-
restricted tetramerwas synthesizedbyBeckman-Coulter (Fullerton,CA).
Results: DCs were primarily of myeloid Langerhans phenotype
(CD11c1, CD14-) and expressed high levels of CD209, HLA-DR
and costimulatory molecules CD80, CD86, and CD83. Primed
and expanded T-cells were predominantly CD62L1CCR7-, indica-
tive of effector status; however, there were also small but distinct
populations CD1271 and CCR71 memory cells. Upon recall with
HA-loaded autologous DC, a 4 to 10-fold increase in the number
of IFN-g producing T-lymphocytes was observed in comparison
to T-cells stimulated with autologous unloaded DCs or allogeneic
DCs loaded with irrelevant antigens. Antigen-specific T-cell func-
tionality was determined by 51Cr lysis assay. Using a peptide library
of predicted HA binding epitopes, we mapped an HA-specific,
DR15-restricted CD4 T-cell epitope (GNLIAPWYAFALSRG)
and documented tetramer-positive CD41 cells in a DR151 back-
ground.
Conclusions: The model demonstrates that HA-specific, HLA-
restricted immune responses may be generated from UCB
lymphocytes and suggests that dendritic cell immunotherapy for
the prevention of influenza might be feasible.243
HUMAN CORONAVIRUS (HCOV) AND RHINOVIRUS (HRHV) INFECTION
AMONG HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) RECIP-
IENTS
Milano, F.1, Campbell, A.P.1,2, Kuypers, J.3, Englund, J.A.2, Callais, C.1,
Corey, L.1, Boeckh, M.1 1Fred Hutchinson Cancer Research Center, Seat-
tle, WA; 2Seattle Children’s Hospital, Seattle, WA; 3University of Wash-
ington, Seattle, WA
Background:Little is known about clinical and virologicmanifes-
tations of HCoV and HRhV infections after HCT. HCoV and
HRhV are not usually associated with severe illness but have been
reported to cause pneumonia in immunocompromised patients.
Methods: From Dec. 2005-June 2008, prospective surveillance
was performed on 215 allogeneic HCT recipients for 100 days
post-HCT.Weekly symptom surveys, nasal washes and throat swabs
were collected and samples were tested by RT-PCR.We tested for 4
different types of HCoV (OC43, 229E, HKU1 and NL63).
Results: Among 215 patients, the cumulative incidence estimate
for HCoV infection at day 100 was 11.6 (95% CI, 7.3–15.9) and
for HRhV was 20.9 (95% CI, 15.5–26.4); median time of first detec-
tion was 54 days (range 2–93) and 38 days (0–93), respectively. Inci-
dent virus infections occurred mostly in winter months for HCoV
whereas HRhV infections occurred year-round. Prolonged viral
shedding for $3 months was observed in 6 (13%) patients with
HRhV and in 4 (16%) with HCoV. Twelve of the 25 (48%) subjects
with HCoV and 4 of 45 (9%) with HRhV detections were asymp-
tomatic during every week of virus detection. An additional 3 pa-
tients with .10 samples positive for HRhV reported symptoms
only once during the duration of positivity. Frequently reported
symptoms associated with HRhV detection included rhinorrhea
(52%), cough (32%), shortness of breath (32%), and wheezing
(22%); symptoms reported with HCoV detections were similar to
those when no virus was detected. Of the 45 cases of HRhV infec-
tion, 43 had upper respiratory infection only (URI) and 2 developed
URI plus lower respiratory infection (LRI). None of the 25 cases of
Poster Session-I 89HCoV infection developed LRI. BAL was performed in 38 (18%)
patients, 6 of whom had HRhV detection in upper respiratory sam-
ples. Two of these BALs tested positive for HRhV.
Conclusion:This prospective study is the first to describe the nat-
ural history of HCoV and HRhV infections during the first 100 days
after HCT. HRhV and HCoV infections were common and pro-
longed shedding may occur. While HRhV frequently caused symp-
tomatic URI and occasionally LRI, there was no apparent
association with either URI or LRI in patients infected with
HCoV in this study group. However, this study does not exclude
the possibility that HCoV is a rare cause of lower tract disease. Stud-
ies are on-going to further investigate this.244
TACROLIMUS AND SIROLIMUS AS GVHD PROPHYLAXIS FOR SIBLING DO-
NOR HEMATOPOIETIC STEM CELL TRANSPLANT (HCT) USING THREE
CONDITIONING REGIMENS; FLUDARABINE-MELPHALAN, FTBI-VP16,
AND BUSULFAN-CYCLOPHOSPHAMIDE
Nakamura, R.1, Rodriguez, R.1, Palmer, J.2, Parker, P.1,
Nademanee, A.1, Shayani, S.3, Smith, E.1, Karanes, C.1, Snyder, D.1,
O’Donnell, M.1, Krishnan, A.1, Pullarkat, V.1, Senitzer, D.1,
Rosenthal, J.4, Kogut, N.1, Forman, S.J.1 1City of Hope National Medical
Center, Duarte, CA; 2City of HopeNationalMedical Center, Duarte, CA;
3City of Hope National Medical Center, Duarte, CA; 4City of Hope
National Medical Center, Duarte, CA
Based on encouraging phase II data, we prospectively tested the
combination of tacrolimus and sirolimus (tacro/siro) as GVHD pro-
phylaxis in patients undergoing HLA-matched sibling donor HCT.
Eighty-five patients were stratified according to conditioning regi-
men as follows: fludarabine-melphalan (FluMel: n 5 46); FTBI-
VP16 (TBI: n 5 28), and busulfan-cyclophosphamide (BuCy: n 5
11).Themedian agewas 47 years (range: 10–67).The patient diagno-
ses were AML (33), ALL (18), NHL/HD (11/3), MDS (6), CML (5),
myeloma (3), MPD (3), and CLL (1). A majority of patients received
a PBSC graft except for five who received a BM graft with the overall
median CD341 cell dose of 5.1  106/kg (range: 1.7–10.5). All pa-
tients engrafted (median neutrophil engraftment: 15 days). Fifty
five of 85 patients are alive after a median follow up of 26 months
(range: 14–37). Twenty-two patients died of relapse while eight
were due to non-relapse causes including acute/chronic GVHD (3),
multi-organ failure (1), mucormycosis (1), leukoencephalopathy (1),
and respiratory failure (1). The probabilities of overall survival
(OS), disease-free survival (DFS), and relapse at 2 years were 66%
(CI: 59–72), 58% (CI: 52–64), and 34% (CI: 28–42), respectively.
The day 100 and 2 year transplant-related mortality (TRM) was
3.6% (CI: 2–12) and 10.2% (CI: 7–20), respectively. Conditioning
regimen was not significantly associated with OS, DFS, relapse, or
TRM. The cumulative incidence of acute GVHD grade II-IV and
III-IVwas 40% (CI: 37–50) and 16% (CI: 12–27), respectively. Four-
teen of 21 patients with grade II GVHD had upper GI involvement
only. There was a trend for higher probability of acute GVHD in pa-
tients conditioned with BuCy compared with TBI and FluMel (64%,
49% and 34%, respectively)(p 5 0.12). The probability of chronic
GVHD was 45% (limited: 14%, extensive: 31%). Thrombotic mi-
croangiopathy (TMA) was a major complication which developed
in 19% of patients, significantly associated with BuCy (55%) com-
pared with TBI (25%) and FluMel (6.5%)(p5 0.005). TMA was re-
versible in all cases, managed by holding tacro and/or siro except for
two who required plasma exchange/hemodialysis. In summary, the
combination of tacro/siro is associated with a low TRM rate over 2
years. The encouraging results on acute GVHD in our study support
the ongoing phase III trial comparing tacro/siro versus tacro/MTX
(CTN 0402). However, TMA was frequently observed and the risk
was significantly greater with BuCy conditioning.245
PREDICTION OF VOD USING BIOMARKERS OF ENDOTHELIAL INJURY
Cutler, C.1, Aldridge, J.2, Kim, H.T.2, Ayanian, S.3, Bradwin, G.3,
Revta, C.1, Murga, G.1, Ho, V.1, Alyea, E.1, Koreth, J.1, Armand, P.1,
Richardson, P.G.1, Soiffer, R.1, Ritz, J.1, Antin, J.H.1 1Dana-Farber
Cancer Institute, Boston, MA; 2Dana-Farber Cancer Institute, Boston,
MA; 3Children’s Hospital, Boston, MAClinical risk factors for VOD are well known, however, predicting
the occurrence of VOD in individuals remains challenging. Since the
primary mechanism of injury in VOD is conditioning-related dam-
age to hepatic sinusoidal endothelial cells and hepatocytes, we mea-
sured soluble biomarkers of endothelial injury in the peri-stem cell
transplant (SCT) period to determine if they correlated with the oc-
currence of VOD.
Methods: 59 patients who underwent HLA-matched donor SCT
received conditioning with cyclophosphamide (1800 mg/m2 x 2) and
TBI (14 Gy) and tacrolimus with sirolimus or methotrexate as
GVHD prophylaxis are included in this analysis. They are stratified
based on the occurrence of VOD (VOD1 n 5 18, VOD- n 5 41),
diagnosed by clinical, radiologic and pathologic criteria. Banked
samples collected after conditioning but prior to SCT (day -1) and
weekly after SCT (day 7, 14, 21) were thawed and analyzed using
commercial ELISA kits and quantified using a VersaMax plate
reader. Von Willebrand Factor (vWF) and thrombomodulin (TM)
were assayed in plasma; E-selectin and soluble intercellular adhesion
molecule-1 (ICAM) were assayed in serum. Assays were performed
in duplicate and the mean of two assays were analyzed. Not all pa-
tients had every time point analyzed due to missing specimens.
The within-sample results were compared using the 2-sided Wil-
coxon rank-sum test using the Bonferroni method to adjust for mul-
tiple comparisons.
Results: Among patients who received sirolimus, levels of vWF,
TM and ICAM were significantly different between VOD1 and
VOD- groups on day -1 (p # 0.04), day17 (p # 0.0001) and
day114 (p # 0.004). E-selectin was only predictive on day17 (p 5
0.009). Using pre-defined thresholds, vWF (.1400 IU/ml) and
TM (.100 ng/ml) levels on day 17 were 100% sensitive and
100% specific in predicting the occurrence of VOD. Biomarkers
could not reliably predict VOD among patients not treated with si-
rolimus. There were no differences in biomarkers among VOD- pa-
tients, suggesting that in the absence of VOD,markers of endothelial
injury are not elevated, even when sirolimus is used.
Conclusions: Plasma vWF and TM and serum ICAM elevations
before and early after SCT can be used to predict the occurrence of
VOD in patients receiving sirolimus. This analysis demonstrates the
contribution of sirolimus to endothelial injury and VOD after SCT,
and may help select patients in whom prophylactic or pre-emptive
strategies against endothelial damage and VOD may be useful.246
CYTOMEGALOVIRUS (CMV) REACTIVATION IN RECIPIENTS OF UMBILI-
CAL CORD BLOOD (UCB): RISK FACTORS AND OUTCOMES
Beck, J.C.1, DeFor, T.E.1, Brunstein, C.G.2, Weisdorf, D.J.2,
Wagner, J.E.1, Verneris, M.R.1 1University of Minnesota, Minneapolis,
MN; 2University of Minnesota, Minneapolis, MN
Pre-transplant CMV serostatus has been shown to be an adverse
risk factor in allo-HCT recipients. The consequences of CMV reac-
tivation after transplantation have not been extensively described in
theUCB setting.We analyzed the impact of pre-transplant CMV se-
ropositivity and CMV reactivation on UCBT outcomes. Between
1994 and 2007, 332 patients with malignancies underwent UCBT
at the University of Minnesota and 54% were CMV seropositive.
AllUCBunits were considered seronegative.While there was a trend
to greater day 100 TRM (p5 0.07), CMV seropositivity was not as-
sociated with survival (p 5 0.55) or relapse (p 5 0.78). For the 180
CMV seropositive patients, the median age at UCBT was 51 years
(range 6–68). Myeloablative conditioning consisting of cyclophos-
phamide (CY) and TBI 13.2 Gy, with ATG (n5 31, 25%) or fludar-
abine (FLU, n5 91, 75%).Myeloablative conditioning was followed
by single (n 5 56, 46%) or double (n 5 66, 54%) UCBT. Reduced
intensity conditioning (RIC) consisted of CY, FLU and TBI 2 Gy
and was followed by double UCBT in all 58 patients. GVHD pro-
phylaxis consisted of cyclosporine/methylprednisone (17%) or cy-
closporine/mycophenolate mofetil (83%). All patients had weekly
screening for CMV reactivation (by pp65 antigenemia or PCR)
and received acyclovir prophylaxis until day 100. The incidence of
CMV reactivation was 51% (92/180) with no difference in recipients
of a myeloablative vs. RIC (p 5 0.33). Among recipients of myeloa-
blative conditioning, CMV reactivation was similar regardless of
GVHD prophylaxis regimen (p 5 0.8). In univariate analysis, the
only variables associated with CMV reactivation were older age
